Immunic Psoriasis Analysis Adds Dose Of Uncertainty To Program

Without disclosing full Phase Ib data, the company reported a higher-than-expected placebo response versus IMU-935. With its second setback this year Immunic has a long path to meaningful data.

Immunic announced an interim analysis of its Phase Ib study of IMU-935 in psoriasis • Source: Shutterstock

Immunic Inc’s psoriasis program faces an uncertain future as the company announced an interim analysis indicating a high placebo response rate in the Phase Ib trial of IMU-935 and a lack of separation between the treatment and placebo arms. The company continues to express confidence in the program, but the announcement sparked uncertainty around the compound and marks Immunic’s second major clinical development setback in four months.

The company announced on 20 October that in a pre-planned interim group-level data analysis of the trial the group averages...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

06 Jun 2025

• By Joseph Haas

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.

Santen Sees Potential In Myopia Market After Ryjunea Approval

06 Jun 2025

• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Europe’s Drugmakers Lament EU Pharma Package

05 Jun 2025

• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Bayer Boosted By Third FDA Approval For Nubeqa

04 Jun 2025

• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

A MoonLake Buyout Would Boost Merck & Co’s Immunology Ambitions

05 Jun 2025

• By Andrew McConaghie

As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.